A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma

Cancer

Volumn 88, Issue 1, 2000, Pages 124-131

  Perez, Edith A ^a,i   Hillman, David W ^a   Stella, Philip J ^b   Krook, James E ^c   Hartmann, Lynn C ^a   Fitch, Tom R ^d   Hatfield, Alan K ^e   Mailliard, James A ^f   Nair, Suresh ^g   Kardinal, Carl G ^h   Ingle, James N ^a  

^a MAYO CLINIC   (United States)

^b Ann Arbor Regional CCOP   (United States)

^c Duluth CCOP   (United States)

^d Scottsdale CCOP   (United States)

^e Carle Cancer Center CCOP   (United States)

^f Missouri Valley Cancer Center   (United States)

^g GEISINGER MEDICAL CENTER   (United States)

^h Ochsner CCOP   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

Breast carcinoma; Carboplatin; First line chemotherapy; Paclitaxel

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CARBOPLATIN; DOXORUBICIN; HEMOPOIETIC GROWTH FACTOR; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; HUMAN; METASTASIS; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033964853     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000101)88:1<124::AID-CNCR17>3.0.CO;2-F     Document Type: Article

References (33)

1. American Cancer Society. Cancer facts and figures - 1999. Atlanta, GA: American Cancer Society, 1999.
2. Honig SF. Hormonal therapy and chemotherapy. In: Harris JR, Morrow M, Lippman ME, Hellman S, editors. Diseases of the breast. Philadelphia, PA: Lipincott-Raven, 1996:669-734.
3. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67.
4. Peretz T, Sulkes A, Chollet P, Gwelmon K, Paridaens R, Gorbonuva V, et al. A multicenter, randomized study of two schedules of paclitaxel in patients with advanced breast cancer [abstract 345]. Eur J Cancer 1995;31:575.
5. Winer E, Berry D, Duggan D, Henderson IC, Cirrincione C, Cooper R, et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer-results from CALGB 9342 [abstract 388]. Proc Am Soc Clin Oncol 1998;17:101a.
6. Mamounas E, Brown A, Smith R, Lembersky B, Fisher B, Wickerham DL, et al. Effect of Taxol duration of infusion in advanced breast cancer (ABC): results from NSAPB B-26 trial comparing 3-to 24-hour infusion of high dose Taxol [abstract 389]. Proc Am Soc Clin Oncol 1998;17:101a.
7. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-81.
8. Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87:1169-75.
9. Fountzilas G, Athanassiades A, Giannakakis T, Bafaloukos D, Karakousis K, Dombros N, et al. A Phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 1996;32A:47-51.
10. Sledge GW, Neuberg D, Ingle J, Martino S, Wood W. Phase III trial of doxorubicin(A) vs. paclitaxel(T) vs. doxorubicin + paclitaxel(A+T) as first-line therapy for metastatic breast cancer, an intergroup trial [abstract 2]. Proc Am Soc Clin Oncol 1997;16:1a.
11. O'Brien MD, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: a Phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 1993;1:2112-7.
12. Martìn M, Dìaz-Rubìo E, Casado A, Santabarbara P, Lopez Vega JM, Adrover E, et al. Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 1992;10:433-7.
13. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KR. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rep 1985;12(Suppl A):51-7.
14. Gelmon KA, O'Reilly SE, Tolcher AW, Campbell C, Bryce C, Ragaz J, et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996;14:1185-91.
15. Sparano JA, Neuberg D, Glick JH, Robert NR, Goldstein LJ, Sledge GW, et al. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Group study. J Clin Oncol 1997;15:1880-4.
16. McCaskill-Stevens W, Ansari R, Fisher W, Pennington K, Dobbs C, Gonin R, et al. Phase II study of biweekly cisplatin (C) and paclitaxel (P) in the treatment of metastatic breast cancer [abstract 144]. Proc Am Soc Clin Oncol 1996;15:120.
17. Natale RB. Preliminary results of a Phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncol 1996;23(Suppl 16):51-4.
18. 2) plus carboplatin in non-small cell lung cancer: a randomized study. Semin Oncol 1997;24(Suppl 12):S12-30,33.
19. Bookman MA, McGuire WP, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, et al. Carboplatin and paclitaxel in ovarian carcinoma: a Phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996;14:1895-902.
20. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
22. Ingle JN, Johnson PA, Suman VJ, Gerstner JB, Mailliard JA, Camoriano JK, et al. A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 1997;80: 218-24.
23. Duffy DE, Santer TJ. Confidence intervals for a binomial parameter based on multistaged tests. Biometrics 1987;43: 81-93.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Cella DF. F.A.C.T. manual: manual for the Functional Assessment of Cancer Therapy (FACT) scales and the Functional Assessment of HIV Infection (FAHI) scale. Chicago, IL: Rush-Presbyterian-St. Luke's Medical Center, 1994.
26. Sparano JA, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC. Phase II trial of doxorubicin plus paclitaxel plus G-CSF in metastatic breast cancer: an Eastern Cooperative Oncology Group study (E4195) [abstract 3]. Breast Cancer Res Treat 1997;46:23.
27. Fountzilas G, Athanassiades A, Papadimitrou V, Dimopoulos M-A, Bafaloukos D, Aravantinos G, et al. Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer. Oncology 1998;12(Suppl 1):45-8.
28. Fountzilas G, Athanassiadis A, Kalogera-Fountzila A, Aravantinos G, Bafaloukos D, Briasoulis E, et al. Paclitaxel by 3-hour infusion and carboplatin in anthracycline-resistant advanced breast cancer. A Phase II study conducted by the Hellenic Cooperative Oncology Group. Eur J Cancer 1997; 33:1893-5.
29. Belani CP, Kearns CM, Zuhowski EG, Erkman K, Hiponia D, Zacharski D, et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small cell lung cancer. J Clin Oncol 1999;17:676-84.
30. Baselga J, Norton L, Albanell J, Kim Y-M, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
31. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cells. Oncogene 1994;9:1829-38.
32. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde T, Fleming W, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 + MBC) markedly increases anticancer activity: a randomized, multinational controlled Phase III trial [abstract 377]. Proc Am Soc Clin Oncol 1998;17:98a.
33. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.